MedTrace Logo

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

NCT03720561 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 312

Last updated 2022-01-03

No results posted yet for this study

Summary

The purpose of this study is to describe the 2-year retention rate of ibrutinib treatment for chronic lymphocytic leukemia (CLL) in Italian routine clinical practice.

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

Ibrutinib

Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.

Sponsors & Collaborators

  • Janssen-Cilag S.p.A.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag S.p.A., Italy Clinical Trial · Janssen-Cilag S.p.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2021-11-12
Completion
2021-11-12
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03720561 on ClinicalTrials.gov